LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Twist Bioscience Corp

Geschlossen

BrancheGesundheitswesen

25.05 -4.57

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.26

Max

26.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

60M

20M

Verkäufe

3.3M

96M

Gewinnspanne

21.227

Angestellte

923

EBITDA

22M

-24M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+44.3% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

17. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-226M

1.6B

Vorheriger Eröffnungskurs

29.62

Vorheriger Schlusskurs

25.05

Nachrichtenstimmung

By Acuity

100%

0%

358 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2025, 23:37 UTC

Heiße Aktien

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. Sept. 2025, 20:41 UTC

Ergebnisse

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. Sept. 2025, 20:30 UTC

Ergebnisse

GameStop 2Q Sales, Profit Rise

9. Sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. Sept. 2025, 21:35 UTC

Ergebnisse

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 21:32 UTC

Ergebnisse

Oracle's Backlog Swells With Big Customer Deals -- Update

9. Sept. 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Sept. 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. Sept. 2025, 20:26 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:23 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:12 UTC

Ergebnisse

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. Sept. 2025, 20:07 UTC

Ergebnisse

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Software Revenue $5.72B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Synopsys 3Q Adj EPS $3.39 >SNPS

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $14.93B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q EPS $1.01 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Synopsys 3Q EPS $1.50 >SNPS

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.35B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.47 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $670M >ORCL

Peer-Vergleich

Kursveränderung

Twist Bioscience Corp Prognose

Kursziel

By TipRanks

44.3% Vorteil

12-Monats-Prognose

Durchschnitt 37.88 USD  44.3%

Hoch 50 USD

Tief 25 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Twist Bioscience Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

6

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

31.56 / 38.6884Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

358 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat